Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 2 1

Status

Completed 2Terminated 1

Sponsor Class

INDUSTRY 3OTHER 2

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3

Conditions

Carcinoma, Hepatocellular 2Liver Neoplasms 1Hepatitis B 1Diarrhea 1Colorectal Neoplasms 1

Interventions

pembrolizumab 1019Carboplatin 959Paclitaxel 932Gemcitabine 793Cisplatin 748Docetaxel 682Bevacizumab 610Pemetrexed 502Nivolumab 486Cyclophosphamide 466Capecitabine 461Fluorouracil 417Dexamethasone 402Rituximab 372Oxaliplatin 347Injections 342atezolizumab 297Trastuzumab 297Leucovorin 286Cetuximab 282Irinotecan 266130-nm albumin-bound paclitaxel 252Prednisone 244Doxorubicin 240Ipilimumab 226Lenalidomide 220Fulvestrant 217fludarabine 214durvalumab 205Erlotinib Hydrochloride 188

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × Interventional × PHY 906 × Clear all
NCT04000737 2025-04-13

YIV-906 (Formerly PHY906/KD018) With Sorafenib in HBV(+) Hepatocellular Carcinoma (HCC)

Yiviva Inc.

Phase 2 Completed
62 enrolled
Gastrointestinal

Hepatitis B, Carcinoma, Hepatocellular

NCT00076609 2007-03-28

Study of Botanical PHY906 Plus Capecitabine for Advanced Unresectable Hepatocellular Carcinoma

PhytoCeutica

Phase 1/2 Completed
31 enrolled
Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

NCT00036517 2005-06-24

Safety Study of the Chemotherapy Modulator PHY906 in Patients With Advanced Colorectal Cancer

PhytoCeutica

Phase 1/2 Terminated
30 enrolled
Gastrointestinal

Diarrhea, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡